Vanderbilt Criteria for Phosphorus Replacement
I cannot identify specific "Vanderbilt criteria" for phosphorus replacement in the provided evidence. The evidence consists primarily of K/DOQI guidelines for managing phosphorus in chronic kidney disease patients, not acute hypophosphatemia replacement protocols that would typically be associated with institutional criteria like "Vanderbilt criteria."
What the Evidence Actually Addresses
The provided guidelines focus on chronic phosphorus management in CKD, not acute phosphorus replacement:
For CKD Patients NOT on Dialysis (Stages 3-4):
- Maintain serum phosphorus ≥2.7 mg/dL (0.87 mmol/L) and ≤4.6 mg/dL (1.49 mmol/L) 1
- Use dietary restriction (800-1,000 mg/day) when phosphorus >4.6 mg/dL 1
- Add phosphate binders if dietary restriction fails 1
For CKD Stage 5/Dialysis Patients:
- Target range: 3.5-5.5 mg/dL (1.13-1.78 mmol/L) 1
- More aggressive phosphate binder therapy when >5.5 mg/dL 1
For Kidney Transplant Patients:
- Replace when phosphorus ≤1.5 mg/dL (0.48 mmol/L) with oral supplements 1
- Consider replacement for levels 1.6-2.5 mg/dL (0.52-0.81 mmol/L) 1
- Target range: 2.5-4.5 mg/dL (0.81-1.45 mmol/L) post-transplant 1
Acute Hypophosphatemia Replacement (From Research Evidence)
The research studies provide some guidance on acute IV replacement for severe hypophosphatemia:
Severity Classification:
- Mild: 2.0-2.5 mg/dL
- Moderate: 1.0-1.9 mg/dL
- Severe: <1.0 mg/dL 2
IV Replacement Protocols:
- For moderate hypophosphatemia (1.6-1.9 mg/dL): 15 mmol sodium phosphate IV over 2 hours, can repeat up to 45 mmol/24 hours 3
- For severe hypophosphatemia: Individualized dosing using formula: phosphate dose (mmol) = 0.5 × body weight × (1.25 - [serum phosphate]), infused at 10 mmol/hour 4
Critical Caveat
The "Vanderbilt criteria" you're asking about likely refers to a specific institutional protocol not included in this evidence base. If you're looking for a specific hospital's phosphorus replacement protocol, you would need to access that institution's internal guidelines directly. The evidence provided focuses on chronic kidney disease phosphorus management rather than acute replacement algorithms used in general hospital or ICU settings.